Sign in
IRWD Stock Price, Chart, Stats & News
Ironwood Pharmaceuticals, Inc.
Save
Ironwood Pharmaceuticals, Inc. (IRWD) does not currently pay a dividend.
704.54M
Market cap
7.02x
Current P/E
12.33x
Forward P/E
IRWD chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 90.58% |
Operating margin | 33.18% |
Pretax margin | 23.65% |
Net margin | 8.11% |
Effective tax rate | 65.70% |
ROA | 6.05% |
ROE | -8.22% |
D/E | -2.28x |
Interest coverage ratio | 3.00x |
IRWD valuation
P/E | 7.02x |
P/S | 1.68x |
P/B | -1.90x |
P/CF | 3.91x |
P/FCF | 3.93x |
P/OCF | 3.91x |
PEG | -1.86x |
EV multiple | 0.95x |
About
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union.
Similar securities
Based on sector and market capitalization
Report issue